Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System HoldingsSTU:2M7C +2.33%76 EBITDA Margin % is 22.99% as of Dec. 2025, which is 43% below its 10-year median of 40.61. GuruFocus rates STU:2M7C with a GF Score™ of 76/100 and a GF Value™ of €1.36 (Fairly Valued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, China Medical System Holdings ranks better than 80.12% on this metric.
China Medical System Holdings (STU:2M7C) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Medical System Holdings EBITDA Margin % Related Terms
China Medical System Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (STU:2M7C) has a EBITDA Margin % of 22.99% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Medical System Holdings and its competitors. This is 43% below median its historical median of 40.61. Over the past decade, China Medical System Holdings' EBITDA Margin % has ranged from 25.84 to 45.24. According to the industry distribution chart, China Medical System Holdings ranks #191 out of 961 companies in the Drug Manufacturers industry, placing it in the top 19.9%.
Is China Medical System Holdings' EBITDA Margin % too high?
China Medical System Holdings' current EBITDA Margin % of 22.99% is 43% below median its 10-year median of 40.61. Over the past 10 years, this metric has ranged from a low of 25.84 to a high of 45.24. The Drug Manufacturers industry median EBITDA Margin % is 12.45. China Medical System Holdings' value of 22.99% is 84.7% above this industry median. Based on the distribution chart, China Medical System Holdings ranks #191 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Medical System Holdings has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #191 out of 961 companies for EBITDA Margin %. This places China Medical System Holdings in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.45. China Medical System Holdings' value of 22.99% is 84.7% above this benchmark. Historically, China Medical System Holdings' own EBITDA Margin % has ranged from 25.84 to 45.24 over the past decade. While the company's 10-year median is 40.61 vs. the industry median of 12.45, China Medical System Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current EBITDA Margin % of 22.99% is 84.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Medical System Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current EBITDA Margin % is 22.99%, which is 43% below median its own 10-year median of 40.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (STU:2M7C) is currently considered Fairly Valued. The stock's GF Value™ is €1.36, compared to a current price of €1.32 — trading 2.9% below its estimated fair value. The current EBITDA Margin % is 22.99%, which is 43% below median its 10-year median of 40.61 and 84.7% above the Drug Manufacturers industry median of 12.45. China Medical System Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Medical System Holdings (STU:2M7C), the current EBITDA Margin % is 22.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (STU:2M7C) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be undervalued.
The current stock price of €1.32 is trading 2.9% below its estimated GF Value™ of €1.36.
GuruFocus considers China Medical System Holdings to be Fairly Valued.
Key valuation signals for STU:2M7C:
EBITDA Margin %: 22.99% (43% below median its 10-year median of 40.61)
GF Value™: €1.36 vs. price of €1.32 (2.9% below fair value)
Industry Position: 84.7% above the Drug Manufacturers median (#191 of 961)
No single metric tells the full story. See the STU:2M7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
76GF Score
Get the complete analysis for STU:2M7C
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2M7C has been successfully added to your 
